Table 1 Characteristics of study patients treated with LAIs
Characteristic | LAI patients (N = 2222) |
|---|---|
Age at index, mean (SD) | 22.9 (4.0) |
 18-25, n (%) | 1832 (82.4) |
 26-35, n (%) | 390 (17.6) |
Gender, n, (%) | |
 Male | 1565 (70.4) |
 Female | 657 (29.6) |
Region, n (%) | |
 Northeast | 428 (19.3) |
 Midwest | 516 (23.2) |
 South | 858 (38.6) |
 West | 407 (18.3) |
 Other/Unknown | 13 (0.6) |
Baseline antipsychotic treatment, n (%) | |
 Treated | 1370 (61.7) |
 Untreated | 852 (38.3) |
DSM-V mental illness comorbidities in 12-month pre-index period, n (%) | |
 Substance-related and addictive disorders | 816 (36.7) |
 Anxiety disorders | 746 (33.6) |
 Bipolar and related disorders | 700 (31.5) |
 Depressive disorders | 552 (24.8) |
 Neurodevelopmental disorders | 413 (18.6) |
 Trauma- and stressor-related disorders | 357 (16.1) |
 Other conditions that may be a focus of clinical attention | 329 (14.8) |
 Sleep-wake disorders | 246 (11.1) |
 Other mental disorders | 201 (9.0) |
 Disruptive, impulse-control, and conduct disorders | 158 (7.1) |
 Personality disorders | 128 (5.8) |
Physical health comorbidities in 12-month pre-index period, n, (%) | |
 Other neurological disorders | 382 (17.2) |
 Hypertension, uncomplicated | 170 (7.7) |
 Obesity | 165 (7.4) |
 Fluid and electrolyte disorders | 151 (6.8) |
Baseline medications | |
 Antipsychotics, n (%) | |
  LAI atypical antipsychotics | 154 (6.9) |
  LAI typical antipsychotics | 206 (9.3) |
  Oral atypical antipsychotics | 1094 (49.2) |
  Oral typical antipsychotics | 188 (8.5) |
 Antidepressants, n (%) | 155 (7.0) |
 Anxiolytics, n (%) | 612 (27.5) |
 Mood stabilizers, n (%) | 841 (37.8) |
 Opioids, n (%) | 434 (19.5) |
LAI initiation | |
 Type of providers at LAI initiation, n, (%) | |
  Psychiatrist | 708 (31.9) |
  Primary care | 68 (3.1) |
  Others | 1446 (65.1) |
 Healthcare setting at LAI initiation, n, (%) | |
  Inpatient stay | 1560 (70.2) |
  ER visit | 120 (5.4) |
  Others (e.g., Outpatient, SNF, OOV) | 542 (24.4) |